Tidemark’s Lipocine LPCN Stock Holding History

Tidemark’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$151	Hold	59	–	–	﹤0.01%	921
2026 Q1	$471	Hold	59	–	–	﹤0.01%	767
2025 Q4	$474	Hold	59	–	–	﹤0.01%	626
2025 Q3	$168	Hold	59	–	–	﹤0.01%	670
2025 Q2	$186	Hold	59	–	–	﹤0.01%	692
2025 Q1	$188	Buy	+59	New	+$228	﹤0.01%	693
2024 Q4	–	Sell	-59	Closed	-$265	–	662
2024 Q3	$265	Hold	59	–	–	﹤0.01%	610
2024 Q2	$486	Hold	59	–	–	﹤0.01%	591
2024 Q1	$307	Hold	59	–	–	﹤0.01%	675
2023 Q4	$165	Buy	+59	New	+$156	﹤0.01%	677

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tidemark's LPCN Position: Q2 2026 in Review

Tidemark held its Lipocine (LPCN) position steady in Q2 2026 at 59 shares worth $151. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Tidemark first reported a position in LPCN in Q4 2023 and has held it in 10 quarters since. The position peaked at $486 in Q2 2024. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Tidemark held 59 shares of Lipocine worth $151 as of Q2 2026.
Tidemark left its Lipocine share count unchanged in Q2 2026.
Lipocine made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #921 holding.
Tidemark first reported a position in Lipocine in Q4 2023 and has held it in 10 quarters since.
Tidemark's Lipocine position peaked at $486 in Q2 2024.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.